Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
GENETIC IMMUNOTHERAPY BY INTRAPLEURAL, INTRAPERITONEAL AND SUBCUTANEOUS INJECTION OF IL-2 GENE-MODIFIED LEWIS LUNG-CARCINOMA CELLS
Autore:
HEIKE Y; TAKAHASHI M; OHIRA T; NARUSE I; HAMA S; OHE Y; KASAI T; FUKUMOTO H; OLSEN KJ; PODACK EE; SAIJO N;
Indirizzi:
NATL CANC CTR,RES INST,DIV PHARMACOL,CHUO KU,TSUKIJI 5-1-1 TOKYO 104 JAPAN NATL CANC CTR,RES INST,DIV PHARMACOL,CHUO KU TOKYO 104 JAPAN NATL CANC CTR,DEPT INTERNAL MED TOKYO JAPAN UNIV MIAMI,SCH MED,DEPT MICROBIOL & IMMUNOL MIAMI FL 00000
Titolo Testata:
International journal of cancer
fascicolo: 6, volume: 73, anno: 1997,
pagine: 844 - 849
SICI:
0020-7136(1997)73:6<844:GIBIIA>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; ADJUVANT IMMUNOTHERAPY; ANTITUMOR IMMUNITY; INTERFERON-GAMMA; WALL SKELETON; FACTOR-ALPHA; CANCER; INTERLEUKIN-2; VACCINATION; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
Y. Heike et al., "GENETIC IMMUNOTHERAPY BY INTRAPLEURAL, INTRAPERITONEAL AND SUBCUTANEOUS INJECTION OF IL-2 GENE-MODIFIED LEWIS LUNG-CARCINOMA CELLS", International journal of cancer, 73(6), 1997, pp. 844-849

Abstract

The induction and augmentation of tumor non-specific immunity and of tumor-specific immunity by intrapleural, intraperitoneal and subcutaneous injection of interleukin-2 (IL-2) gene-modified Lewis lung carcinoma (LLC) cells (LLC-IL2) was tested in C57BL/6 mice. Intrapleural injection of LLC cells induced lung tumors with a malignant effusion, intraperitoneal injection induced peritoneal tumors with ascites and subcutaneous injection induced subcutaneous tumors. Intrapleural injection of irradiated LLC-IL2 cured pre-existing lung LLC tumors and extended the survival of the mice but did not affect survival of mice with pre-existing peritoneal tumors nor did it affect the growth of s.c. tumors. Intraperitoneal injection of irradiated LLC-IL2, cured pre-existing LLC peritoneal tumors and extended the survival of the mice but did not affect survival of mice heaving lung tumors nor did it affect the growth of s.c. tumors. Subcutaneous injection of irradiated LLC-IL2 did not affect the growth of preexisting s.c. tumors and also did not improve survival of mice bearing the lung or peritoneal tumors. Injection with irradiated LLC-IL2 by all routes, i.e., intrapleural, intraperitoneal and s.c., protected against subsequent re-challenge with LLC. Eight days after the initial immunization (early stage of immunization), nonadherent mononuclear cells in the peritoneal cavity of the mice treated with intraperitoneal injection of irradiated LLC-IL2 displayed enhanced cytotoxicity against LLC, B16-F10 and P815 cells, while the cytotoxic activity of spleen cells in the same mice did not change. The efficiency of induction of tumor-specific immunity was the strongest after intraperitoneal immunization and weakest after s.c. immunization. In vitro analysis using the spleen cells of mice immunized with irradiated LLC-IL2 suggested that CD8(+) T cells play a key role in tumor-specific immunity. (C) 1997 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 03:43:14